Axogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.52 USD | -2.46% |
|
+3.30% | +10.10% |
Jul. 01 | Raymond James Initiates AxoGen at Outperform With $13 Price Target | MT |
Jun. 24 | Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.10% | 329M | |
+0.59% | 204B | |
+3.92% | 178B | |
+30.07% | 156B | |
+32.42% | 113B | |
+1.98% | 64.26B | |
+19.65% | 54.98B | |
-1.86% | 47.44B | |
-9.53% | 36.7B | |
-1.28% | 34.84B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study